Nav: Home

Early detection of leukemia patients' resistance to therapy

July 28, 2016

Australian researchers have made a world-first breakthrough in the early detection of patients' resistance to a common treatment for chronic myeloid leukemia.

The discovery offers some hope that the patients' treatment could be changed sooner to improve their chances of survival.

The researchers - based in the Cancer Theme at the South Australian Health & Medical Research Institute (SAHMRI) and the University of Adelaide's School of Medicine - have developed a new test that they believe could be adopted by doctors worldwide.

The results of this research are now published online ahead of print in the international journal Leukemia.

Lead author and postdoctoral researcher Dr Laura Eadie says one-in-five chronic myeloid leukemia (CML) patients are resistant to the leading treatment of their condition.

"The development of the targeted drug Glivec for chronic myeloid leukemia has been one of the most remarkable success stories in cancer treatment over the past two decades. This is because the drug targets the mutant protein that causes their leukemia," Dr Eadie says.

"However, about 20% of patients have a poor response to Glivec, and until now we haven't fully understood why. Unfortunately, this means that one-in-five patients could be receiving treatment that ultimately is not benefitting them, losing response to therapy and reducing their chances of survival."

The study looked at the role of P-glycoprotein, a protein that pumps many drugs - including Glivec - out of leukemia cells.

"Some patients were found to have higher levels of P-glycoprotein in their leukemic cells after just a few weeks of starting therapy. These patients were much more likely to develop resistance to Glivec later on," Dr Eadie says.

"We've found the greater the increase in P-glycoprotein in patients, the greater their risk is of becoming resistant and not responding to their drug any more, or even succumbing to their disease."

The research team's work shows, for the first time, that assessing a patient's levels of the P-glycoprotein soon after they start receiving Glivec therapy will help to predict that patient's long-term response to the drug.

"This new test, developed in our laboratory, may provide an opportunity for doctors around the world to change treatment strategies for those patients most at risk of doing poorly on Glivec before they actually lose response to the therapy," Dr Eadie says.

Dr Eadie is also the recipient of a 2016 Fulbright South Australia Postdoctoral Scholarship. Next month, she will travel to the United States to continue research into leukemia, based at the St. Jude Children's Research Hospital in Tennessee.

This work will continue her focus on the effectiveness of leukemia treatments and the mechanisms of resistance in patients.

"I hope that by better understanding the key drivers of response and resistance in patients, these research findings will help to inform clinical practice and ensure the best possible chance of patient survival," she says.
SAHMRI's Cancer Theme is supported with funding from the Cancer Council's Beat Cancer Project.

Media contact:

Dr Laura Eadie
Postdoctoral Researcher
Cancer Theme, SAHMRI; School of Medicine, University of Adelaide

University of Adelaide

Related Leukemia Articles:

Vitamin B6, leukemia's deadly addiction
Researchers from CSHL and Memorial Sloan Kettering Cancer Center have discovered how Acute Myeloid Leukemia is addicted to vitamin B6.
Artificial intelligence tracks down leukemia
Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia -- with high reliability.
Milestone reached in new leukemia drug
Using a chemical compound called YKL-05-099, a team of cancer researchers from CSHL and the Dana Farber Institute was able to target the Salt-Inducible Kinase 3 (SIK3) pathway and extend survival in mice with MLL leukemia.
The drug combination effective against bovine leukemia
Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.
Towards a safer treatment for leukemia
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the Children's Cancer Institute, Australia, have found a safer treatment for a specific type of leukemia.
Research paves way for new source for leukemia drug
Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.
An atlas of an aggressive leukemia
A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.
Finding second hits to knock out leukemia
Targeted drugs are a cornerstone of personalized medicine, yet come with important drawbacks.
Understanding the emergence of leukemia
Acute T-cell lymphoblastic leukemia is a rare type of blood cancer that affects mostly children.
New treatment approach for leukemia
An international research team led by researchers from Vetmeduni Vienna have made an important discovery that could lead to a better understanding of lymphocytic leukemia.
More Leukemia News and Leukemia Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at